Similarly, the RENAAL trial (short for Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) in 1,513 patients with type 2 diabetes and nephropathy showed that losartan significantly reduced the risk of doubling serum creatinine and progression to ESRD compared with placebo [43]. Here, AGT is linked to type 2 diabetes mellitus.